| Profile | GDS2987 / GI_44680115-A |
| Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
| Organism | Homo sapiens |
| Sample | Title | Value | Rank |
|---|---|---|---|
| GSM214810 | HMVEC_vehicle_rep1 | 7.4 | 27 |
| GSM215244 | HMVEC_vehicle_rep2 | ||
| GSM215253 | HMVEC_vehicle_rep3 | 9.1 | 30 |
| GSM215254 | HMVEC_atorvastatin_rep1 | 4.7 | 13 |
| GSM215282 | HMVEC_atorvastatin_rep3 | 0.2 | 0 |
| GSM215344 | HMVEC_atorvastatin_rep2 | 3.2 | 8 |
| GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | ||
| GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 8.3 | 17 |
| GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 7.3 | 13 |
| GSM215294 | HMVEC_SLx2119_rep1 | ||
| GSM215295 | HMVEC_SLx2119_rep2 | ||
| GSM215296 | HMVEC_SLx2119_rep3 | 7.1 | 12 |
| GSM215297 | PASMC_vehicle_rep1 | 22.3 | 33 |
| GSM215298 | PASMC_vehicle_rep2 | 24.4 | 36 |
| GSM215310 | PASMC_vehicle_rep3 | ||
| GSM215311 | PASMC_atorvastatin_rep1 | 1.2 | 2 |
| GSM215312 | PASMC_atorvastatin_rep2 | 23.1 | 35 |
| GSM215313 | PASMC_atorvastatin_rep3 | 5.4 | 8 |
| GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 12.4 | 21 |
| GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 6.2 | 13 |
| GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 36.3 | 52 |
| GSM215327 | PASMC_SLx2119_rep1 | ||
| GSM215328 | PASMC_SLx2119_rep2 | ||
| GSM215329 | PASMC_SLx2119_rep3 | 6.6 | 13 |
| GSM215330 | Fibroblasts_vehicle_rep1 | 11.7 | 27 |
| GSM215331 | Fibroblasts_vehicle_rep2 | ||
| GSM215332 | Fibroblasts_vehicle_rep3 | 7.5 | 25 |
| GSM215333 | Fibroblasts_atorvastatin_rep1 | ||
| GSM215334 | Fibroblasts_atorvastatin_rep2 | ||
| GSM215335 | Fibroblasts_atorvastatin_rep3 | 16.2 | 38 |
| GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | ||
| GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | ||
| GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | ||
| GSM215339 | Fibroblasts_SLx2119_rep1 | ||
| GSM215340 | Fibroblasts_SLx2119_rep2 | ||
| GSM215341 | Fibroblasts_SLx2119_rep3 |